GW Pharma Takes A Step Toward Diversifying

GW Pharma Takes A Step Toward Diversifying

Being a one-trick pony can always prove risky. This rationale seems to have dawned on GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH), a biopharmaceutical company specializing in prescription cannabinoid medicine.

Risk Mitigation Through Diversification

The company announced Tuesday positive top-line results from a mid-stage placebo-controlled study of a proprietary combination of tetrahydrocannabinol, or THC, and cannabidiol, or CBD, for treating glioblastoma multiforme, or GBM. This is seen as the company’s

... read more at: https://www.benzinga.com/general/biotech/17/02/9003650/gw-pharma-takes-a-step-toward-diversifying

by